Dibekacin (3',4'-dideoxykanamycin B) is an aminoglycoside antibiotic. It is a semisynthetic derivative of kanamycin developed by Hamao Umezawa and collaborators for Meiji Seika.[1][2]
Clinical data | |
---|---|
Trade names | Panimycin, Tokocin |
Other names | 3',4'-Dideoxykanamycin B |
AHFS/Drugs.com | International Drug Names |
ATC code | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
PDB ligand | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.047.316 |
Chemical and physical data | |
Formula | C18H37N5O8 |
Molar mass | 451.521 g·mol−1 |
3D model (JSmol) | |
| |
|
It has been used in combination with sulbenicillin.[3]
References
edit- ^ Umezawa H, Umezawa S, Tsuchiya T, Okazaki Y (July 1971). "3',4'-Dideoxy-Kanamycin B Active Against Kanamycin-Resistant Escherichia coli and Pseudomonas aeruginosa". The Journal of Antibiotics. 24 (7): 485–487. doi:10.7164/antibiotics.24.485. PMID 4998037.
- ^ Umezawa H (November 1982). "Découverte de la dibékacine et de ses aspects chimiques [Discovery of dibekacin and its chemical aspects]". La Nouvelle Presse Médicale. 11 (46): 3379–84. PMID 7155844.
- ^ Aonuma S, Ariji F, Oizumi K, Konno K (June 1987). "Electron microscopy of Pseudomonas aeruginosa treated with sulbenicillin and dibekacin". Tohoku J. Exp. Med. 152 (2): 119–28. doi:10.1620/tjem.152.119. PMID 3114912.